ANZCTR search results

Incidence of venous thromboembolism (VTE) in adult nephrotic syndorme is 25-30% and this risk is inversely related to serum albumin (protein) level. This study will investigate whether apixaban (new oral anticoagulant) is as effective as warfarin which is prescribed routinely when patients serum albumin level is very low. Measurement of apixaban in this study will give a good insight into pharmacokinetic of the drug in nephrotic syndrome.

We plan to determine if narrow (targeted) spectrum antibiotics have the same outcomes as broad spectrum antibiotics when treating mild or moderate diabetic foot infections. We know through research that often diabetic foot infections have two main bacteria present, and more often than not, these infections can be treated with a narrow targeted spectrum antibiotic.

An emerging body of research has shown promising effects of exercise-based injury prevention programs (IPPs) in reducing knee injury risk. However, the efficacy of IPPs as reflected in clinical trials have not been replicated in real-world practice largely due to lack of compliance and implementation support. Individualized IPPs targeted to specific biomechanical components may provide the most prudent and effectual implementation strategy by specifically targeting high risk groups. However, the individualization process is hampered by the absence of field-based objective screening methods to stratify risk according to trunk dominance deficits, and a lack of consensus on the ‘best’ combination of IPP components. Thus, the objectives of this study are 1) to identify the best combination of field-based tests to screen for trunk dominance deficits, and 2) to explore the effects of an injury prevention program individualized according to trunk dominance screening results in reducing knee injury risk in athletes. Study hypotheses: 1) that field-based tests for trunk dominance deficits are a valid and reliable alternative compared to three-dimensional biomechanical motion analysis; 2) that individualization of IPPs are more effective in decreasing trunk dominance deficits than generic IPPs

Whist palliative care is highly effective for patients with dementia and their carers it is rarely accessed. We hypothesize that the provision of education, advance care planning and better referral to palliative care for carers will reduce the number of people with dementia that die in hospital and result in improvements in systems and patients centered outcomes. Therefore, this research is about increasing access to palliative care for a group of patients that are currently underrepresented.

This study aims to evaluate whether stereotactic ablative radiotherapy (SABR) is a reasonable and safe treatment option for patients with non-small cell lung cancer (NSCLC) where their cancer is large and/or has also spread to the nearby lymph nodes. Who is it for? You may be eligible to join this study if you are aged 18 or older with a diagnosis of stage III or IV non-small cell lung carcinoma and ineligible for standard of care concurrent chemo-radiotherapy. Study details Participants in this study will undergo stereotactic ablative radiotherapy (SABR). SABR is a specialised form of radiotherapy whereby large doses of radiation are given in fewer treatments. Participants will attend between 6-12 SABR sessions across 2-3 weeks, and will then be followed up regularly post radiotherapy, in order to evaluate treatment safety, quality of life, tumour response and survival. It is hoped this research will contribute to the field of oncology and improve the health outcomes of patients with lung cancer.

This study will determine if the use of adavosertib (cohort 1 & 2) or ceralasertib (cohort 3) as monotherapy provides clinical benefit to patients with high grade serous ovarian cancer Who is it for? You may be eligible to join this study if you are aged 18 and above and have platinum resistant high grade serous ovarian cancer with Cyclin E1 over-expression Study details Participants in this study are now being enrolled into an additional third cohort. Cohort 1 and 2 enrolled 71 participants with Cyclin E1 over-expression (Non-amplified or Amplified). who received the same intervention: daily oral adavosertib tablet from Day 1-5 and Day 8-12 of a 21-day cycle for a maximum of 24 months. Cohort 3 plans to enrol 32 participants with Cyclin E1 over-expression (Non-amplified or Amplified). Participants will receive twice daily oral ceralasertib tablets from day 1-14 of a 28 day cycle for a maximum of 24 months. Patients will undergo 4-weekly appointments for their treatment duration, have bloods taken for translational research and may also be required to have a biopsy performed after the end of their first cycle. All participants will be monitored regularly in order to assess clinical response and treatment safety. It is hoped that IGNITE will provide clinical benefit to patients with high grade serous ovarian cancer who have Cyclin E1 expression and will be able to provide a new treatment option for patients with this genetic fault.

The transition from the supported environment of tertiary medical school into the workforce poses a potentially stressful period for a new doctor. Compounding this, many graduates describe feeling under supported within this new role. This pilot project will see initiation of the “Resident Ready Network” (RRN), a near-peer mentoring program, linking graduating students with junior doctors in the hospital system in Brisbane. We hope that the RRN can be the catalyst for lasting relationships and yield benefits to those who engage by helping to develop an awareness of work life balance as well as support mechanisms available to new doctors. The researchers hypothesize that this program will be acceptable and helpful to these transitioning students and that supporting them in this fashion may even have flow on effects in decreasing their stress levels. We will be analysing stress levels as well as user satisfaction at varying time points throughout the study and engaging with users at it’s 12 month conclusion to ensure the program is built for purpose.

This study aims to compare the effect on falls and other measures of health and wellbeing of: a) a group-based yoga exercise program over 12 months, and b) a seated unsupervised yoga relaxation program over 12 months. Participants allocated to the group-based yoga exercise program will attend either face-to-face yoga classes at established yoga studios with experienced yoga teachers or online classes delivered via Zoom for one hour, twice weekly for 40 weeks. Participants allocated to the yoga relaxation program group will attend two either face-to-face or online one-hour workshops to learn a relaxation yoga program. We hypothesise that greater effects on the rate of falls will be evident from the group-based yoga exercise program compared to the yoga relaxation program.

Bionomics Limited is developing BNC210 for the treatment of anxiety, and trauma- and stressor-related, disorders including Post-Traumatic Stress Disorder (PTSD). This single-centre study, will evaluate the pharmacokinetic profile, as well as the safety and tolerability, of single ascending doses of BNC210 in five healthy male volunteers. Participants will receive single doses of 600 mg, 900 mg and 1200 mg BNC210 as a tablet formulation, during three separate dose periods. There will be a minimum 5 day washout period between each dose period.

The aim of this study is to develop an acceptable, useful, and practical training program, BipolarWISE, to assist adults with bipolar disorder to manage their condition and enhance their quality of life. BipolarWISE is an online group and individual intervention with an optional website component for adult family members/friends who support a person with bipolar disorder and would like to better understand and deal with the disorder and maintain their own wellbeing. The feedback from participants will assist in refining the final program which we aim to test in a large trial. If it is effective, the program can be disseminated to those affected by bipolar disorder.